This induces acetaldehyde metabolic dysfunction and drives tumor metabolic reprogramming, with SAE1-mediated KLF9 inhibition correlating positively with poor prognosis and metastatic risk in HCC patients (31). This evidence concerns the gene KLF9 and hepatocellular carcinoma.